Please login to the form below

Not currently logged in
Email:
Password:

Sanofi’s US pharma head joins Synta as CEO

Anne Whitaker also has experience at GSK
synta-anne-whitaker

Synta Pharmaceuticals has named the former head of Sanofi's pharma operations in the US and Canada as its new CEO.

Anne Whitaker served as president, North America pharmaceuticals, at Sanofi since September 2011 overseeing all pharma and consumer healthcare operations within the region. She also served as a member of Sanofi's global leadership team, global commercial operations committee and US regional management committee.

She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases.

“Synta presents an exciting opportunity defined by a late stage product, ganetespib, that has shown promising activity in multiple indications and a pre-clinical programme, HDC, that has significant potential to generate new drug candidates,” said Whitaker.

Prior to joining Sanofi in 2011, Whitaker spent nearly two decades at GlaxoSmithKline (GSK), progressing through the ranks to eventually hold a senior VP role. She began her career at Delta Communications before joining the Upjohn Company in 1991 as a metabolic disease specialist.

14th August 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics